DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Hennekam syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHennekam syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hennekam syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
FAT atypical cadherin 4 (FAT4) — FAT4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet cacdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8EGW · 2.3 Å · ligand CACODYLATE ION (CAC). Experimental structure, not a prediction.
What the evidence adds up to
Hennekam syndrome is a rare autosomal recessive disorder first described in 1989. The literature up to May 2023 covers more than 50 reported cases. The core features are congenital lymphoedema, usually appearing at birth or in early infancy as swelling of the limbs, genitals, face and eyes, and intestinal lymphangiectasia, which can cause protein-losing enteropathy, mild growth retardation, peripheral oedema and ascites. Biochemical findings include hypogammaglobulinaemia, hypoalbuminaemia, lymphopenia and elevated alpha-1 antitrypsin. Seizures, mild mental retardation and facial anomalies are consistently described.
A 1995 case report added two previously unreported manifestations: an ectopic kidney and craniosynostosis of the coronal suture. That report noted the molecular basis of Hennekam syndrome was then unknown. A 1999 paper described the use of radionuclide lymphoscintigraphy to verify the lymphoedematous component in a diagnostically difficult case. A 2024 report described the first neurosurgical intervention in a Hennekam patient, a craniotomy to resect an intra-axial lesion in a patient presenting with seizures; the authors provided a literature review of central nervous system lesions in the syndrome.
No drug treatment is mentioned in any of these abstracts. No clinical trial data exist. The molecular basis of the syndrome remains incompletely characterised, and no targeted therapy or repurposing candidate has been tested. What is missing is a clear molecular target, any preclinical or clinical drug testing, and a patient stratification strategy that might distinguish the lymphatic, neurological and renal components of the disease.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1995 · 40 citations
Craniosynostosis and kidney malformation in a case of Hennekam syndrome
AbstractHennekam syndrome is a rare autosomal recessive syndrome which was described for the first time in 1989. Here, we present a girl with intestinal lymphangiectasia, severe lymphedema of limbs, seizures, mild mental retardation, and facial anomalies consistent with the diagnosis of Hennekam syndrome. In addition, she had an ectopic kidney and craniosynostosis of the coronal suture, 2 manifestations not previously reported in this syndrome. While the molecular basis of Hennekam syndrome remains, as yet, unknown, this report illustrates its variable clinical expression.
Lymphoscintigraphic Manifestations of Hennekam Syndrome
AbstractHennekam syndrome is a rare, recently described genetic disorder in which facial anomalies and mental retardation accompany congenital lymphedema and intestinal lymphangiectasia. Several other somatic abnormalities have variously been described, as have milder degrees of lymphatic dysfunction. The authors herein describe a case of Hennekam syndrome in which the diagnostic difficulties were partially overcome by the judicious use of radionuclide scintigraphy to verify the lymphedematous component of the patient's presentation.
Neurology and Clinical Neuroscience · 2024 · 0 citations
Surgical resection of a symptomatic intra‐axial lesion in a patient with Hennekam's syndrome: Case report with review of the literature
AbstractAbstract Hennekam syndrome (HS) is a rare genetic disorder involving malformations of the lymphatic system. Structural abnormalities and malformations within the central nervous system (CNS) have also been reported along with intellectual disability and developmental delay. We report a patient with HS who presented with seizures and was found to have an intra‐axial lesion, which was resected via craniotomy. While this case represents, to our knowledge, the first instance in the literature that a HS patient has been treated for a CNS abnormality via neurosurgical intervention, we provide a literature review of CNS lesions in patients with HS.
Ġylym men densaulyķ saķtau. · 2023 · 0 citations · open access
HENNEKAM SYNDROME: LITERATURE REVIEW
AbstractIntroduction Hennekam syndrome is an autosomal recessive disease with lymphangiectasia, severe peripheral lymphedema, abnormalities of the face, cramps, mild growth and mental retardation. The aim of the study to describe the clinical characteristics of Hennekam syndrome. Search strategy. The databases of Scopus, Web of Science, and PubMed were used to conduct a comprehensive literature search. Complete publications that had been released in peer-reviewed journals up through May 2023 were chosen. Search parameters included the terms "Hennekam syndrome" and "Lymphedema-Lymphangiectasia-Mental Retardation Syndrome." Thus, 83 publications were discovered, from which 53 articles were chosen. Results: The literature describes more than 50 cases Hennekam syndrome. Lymphedema, resulting hypoplasia lymphatic system usually appears at birth and in early infancy, in the form of swelling of limbs, genitals, face and eyes. Intestinal lymphangiectasia can lead to protein-losing enteropathy, mild growth retardation, peripheral edema, and ascites. At biochemical study determined hypogammaglobulinemia, hypoalbuminemia, lymphopenia and increased alpha-1 antitrypsin. In this article, a review of the literature and descriptions of each reported case of Hennekam syndrome were made. Введение Синдром Хеннекама представляет собой аутосомно-рецессивное заболевание с лимфангиэктазией, тяжелой периферической лимфедемой, аномалиями лица, судорогами, умеренным ростом и умственной отсталостью. Цель исследования — описать клинические характеристики синдрома Хеннекама. Стратегия поиска. Для проведения всестороннего поиска литературы использовались базы данных Scopus, Web of Science и PubMed. Были выбраны полнотекстовые публикации, опубликованные в рецензируемых журналах до мая 2023 года. Параметры поиска включали термины «синдром Хеннекама» и «синдром лимфедема-лимфангиэктазия-умственной отсталости». Таким образом, было обнаружено 83 публикации, из которых были отобраны 53 статьи. Результаты. В литературе описано более 50 случаев синдрома Хеннекама. Лимфедема, возникающая в результате гипоплазии лимфатической системы, проявляется обычно при рождении и в раннем детстве в виде отека конечностей, половых органов, лица и глаз. Кишечная лимфангиэктазия может привести к энтеропатии с потерей белка, легкой задержке роста, периферическим отекам и асциту. При биохимическом исследовании определяются гипогаммаглобулинемия, гипоальбуминемия, лимфопения и повышение уровня альфа-1-антитрипсина. В статье проведен анализ литературы и описание всех опубликованных случаев синдрома Хеннекама. Кіріспе Хеннекам синдромы лимфангиоэктазиямен, ауыр шеткергі лимфедемамен, бет әлпетіндегі ауытқулармен, құрысулармен, орташа бойлық және ақыл-ой кемістігімен жүретін аутосомды-рецессивті ауру. Зерттеудің мақсаты - Хеннекам синдромының клиникалық сипаттамаларын сипаттау. Іздеу стратегиясы. Әдебиетті жан-жақты іздеу үшін Scopus, Web of Science және PubMed дерекқорлары пайдаланылды. 2023 жылдың мамырына дейін рецензияланған журналдарда жарияланған толық жарияланымдар таңдалды. Іздеу параметрлері «Хеннекам синдромы» және «лимфедема-лимфангиоэктазия-ақыл-ой кемістігі синдромы» терминдерін қамтиды. Осылайша, 83 жарияланым табылды, оның ішінде 53 мақала іріктелді. Нәтижелер. Әдебиетте Хеннeкам синдромымен ауырған 50 астам науқас сипатталған. Лимфедема лимфа тамырларының дұрыс дамымауы әсерінен туған кезде немесе ерте нәрестелік кезеңде аяқтардың, жыныс мүшелерінің, беті мен көзінің ісінуімен көрінеді. Ішектік лимфангиэктазия әсерінен ақуыз жоғалтумен жүретін энтеропатия дамиды, бұл даудың артта қалуы және ісіну мен асциттің дамуымен жүреді. Биохимиялық зерттеу кезінде гипогаммаглобулинемия, гипоальбуминемия, лимфопения және альфа-1 антитрипсиннің жоғарлауы байқалады. Баспаға шыққан барлық клиникалық жағдайлар жинақталып, әдеби шолу жасалған.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
